Evaluating the Impact of Benefit Reassessment Outcomes for Orphan Drugs Surpassing the Revenue Limit in Germany

Previous PostA Global Comparative Evaluation of Health Technology Assessment Outcomes for Non-Orphan, Orphan, and Ultra-Orphan Drugs